Kevin McAllister

Kevin McAllister has over 30 years of work experience in the biotechnology and pharmaceutical industry. Kevin began their career in 1988 as a Project Team Head and International Project Team Member at Sandoz Research Institute Berne Ltd. Kevin then moved on to become the Laboratory Chief and Head of CNS In Vivo Evaluation at the same company. In 2000, they joined Neuroscience Development Franchise at Novartis Pharma as a Principal Medical Scientific Expert, Executive Director, and Head of Neuropsychiatry Research, as well as a Research representative on Neurosciences PRIDE (PRoof-of Research in DEvelopment): Early R&D team. In 2015, they became the Managing Director at Neurenable GmbH, and in 2018, they took on the role of Head of Translational Development at Stalicla. In 2020, they became the Founder and Chairman of Amphilix AG, as well as the Interim Chief Scientific Officer at SOM Biotech.

Kevin McAllister has an Executive MBA from IMD, Lausanne, Switzerland, a Postdoctoral research from LSU, Shreveport LA, USA in Neurobiology of drug addiction, and a PhD from Swansea University in Behavioural Pharmacology.